Evidence map›Paper›PMID 42203856›Full record

ArticleScientific reports2026

Silver-Zinc oxide nanocomposites: a green approach to mitigate herpes simplex virus type 1 challenges.

Roghayeh Babaei, Somayeh Daneshjoo, Ahmad Tavakoli, Seyed Jalal Kiani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Roghayeh BabaeiDepartment of Medical Nanotechnology, TeMS.C. Islamic Azad University, Tehran, Iran.
Somayeh DaneshjooDepartment of Medical Nanotechnology, TeMS.C. Islamic Azad University, Tehran, Iran.
Ahmad TavakoliBiological Products and Blood Safety Research Center, High Institute for Research and Education in Transfusion Medicine, P.O. Box: 14665-1157, Tehran, Iran. A.tavakoli@tmi.ac.ir.
Seyed Jalal KianiDepartment of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herpes simplex virus type 1 (HSV-1) remains a significant global health challenge due to its high prevalence, recurrent infections, emergence of drug-resistant viral strains, and adverse effects associated with conventional antiviral therapies. In this study, silver-zinc oxide nanocomposites (Ag-ZnONPs) were synthesized using Nigella sativa extract and evaluated for antiviral activity against HSV-1 alongside ZnONPs, AgNPs, and calcined Ag-ZnONPs (Ag-ZnONPs-K). Characterization confirmed nanoparticle formation with sizes of ~ 35-50 nm and zeta potentials ranging from - 15.5 to - 25.5 mV. Cytotoxicity assays showed CC

Indexed as

Antiviral AgentsHerpesvirus 1, HumanNanocompositesSilverZinc OxideAnimalsChlorocebus aethiopsGreen Chemistry TechnologyMetal NanoparticlesPlant ExtractsVero CellsAntiviral AgentsPlant ExtractsSilverZinc OxideAntiviral activityCytotoxicityGreen synthesisHSV-1NanoparticlesNigella sativaReal-Time PCRSilver-Zinc oxide nanocomposites

Identifiers

PMID42203856
PMCPMC13438579

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.